21,536 active cure trials—signal flow continues
Today’s signal set shows the cure pipeline staying busy: 7 new Wire signals and 9 new Cure research items arrived in the last 24 hours, while global active cure-related trials remain at 21,536. The most actionable theme in the reported Cure developments is immune engineering: non-human primate data suggest that tuning the ratio of nucleoside-modified versus unmodified mRNA in mRNA-LNP boosting can modulate vaccine-elicited CD8+ T cell responses, with IL-12 involvement also highlighted. At the same time, several items stress causal inference and real-world disease complexity—from Mendelian randomization testing vitamin D’s role in EBV susceptibility to large-scale community modeling for malaria–schistosomiasis co-infection. These are incremental, not instantaneous victories, but together they strengthen the evidence stack that will determine which interventions scale. The window is still open.
In non-human primates, tuning the nucleoside-modified versus unmodified mRNA ratio in mRNA-LNP boosting was reported to affect vaccine-elicited CD8+ T cell responses with IL-12 boosts.
Better control of immune response quality and a clearer map of causal risk factors and co-infection determinants can accelerate which therapies and prevention strategies scale across major diseases.
With 7 new Wire signals and 9 new Cure research items in 24 hours, prioritize follow-through on the strongest mechanistic immune-engineering and causal-inference leads now, before the next evidence cycle closes.